Movement Alert｜WuXi XDC Falls 3.59% in Regular Trading, Buyback Efforts Fail to Stem Selling Pressure Across WuXi Group

Market Focus06-09 09:49

On June 9, WuXi XDC fell 3.59% in regular trading, trading at HK$44.94/share, with trading volume of HK$46.07 million. The stock has now dropped over 21% below its recent buyback average price of HK$57.3, signaling deepening weakness.

On the news front, the company previously disclosed that its professional trustee repurchased 5.702 million shares at an average price of HK$57.3, totaling approximately HK$327 million. Parent company WuXi Biologics also has a buyback plan of up to US$400 million, bringing the WuXi group total repurchase scale to US$500 million. Despite this intensive buyback campaign, selling pressure remains dominant and the stock continues to decline.

Within the Life Sciences Tools and Services sector, the entire WuXi group came under broad pressure. WuXi Biologics fell 4.81%, WuXi AppTec fell 4.7%, GenScript Biotech fell 4.3%, XtalPi fell 3.1%, and Insilico fell 2.01%, reflecting persistent sector-wide headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134928472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134928472","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Falls 3.59% in Regular Trading, Buyback Efforts Fail to Stem Selling Pressure Across WuXi Group","media":"Market Focus","content":"<p><p>On June 9, WuXi XDC fell 3.59% in regular trading, trading at HK$44.94/share, with trading volume of HK$46.07 million. The stock has now dropped over 21% below its recent buyback average price of HK$57.3, signaling deepening weakness.</p><p>On the news front, the company previously disclosed that its professional trustee repurchased 5.702 million shares at an average price of HK$57.3, totaling approximately HK$327 million. Parent company WuXi Biologics also has a buyback plan of up to US$400 million, bringing the WuXi group total repurchase scale to US$500 million. Despite this intensive buyback campaign, selling pressure remains dominant and the stock continues to decline.</p><p>Within the Life Sciences Tools and Services sector, the entire WuXi group came under broad pressure. WuXi Biologics fell 4.81%, WuXi AppTec fell 4.7%, GenScript Biotech fell 4.3%, XtalPi fell 3.1%, and Insilico fell 2.01%, reflecting persistent sector-wide headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Falls 3.59% in Regular Trading, Buyback Efforts Fail to Stem Selling Pressure Across WuXi Group</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Falls 3.59% in Regular Trading, Buyback Efforts Fail to Stem Selling Pressure Across WuXi Group\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-09 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 9, WuXi XDC fell 3.59% in regular trading, trading at HK$44.94/share, with trading volume of HK$46.07 million. The stock has now dropped over 21% below its recent buyback average price of HK$57.3, signaling deepening weakness.</p><p>On the news front, the company previously disclosed that its professional trustee repurchased 5.702 million shares at an average price of HK$57.3, totaling approximately HK$327 million. Parent company WuXi Biologics also has a buyback plan of up to US$400 million, bringing the WuXi group total repurchase scale to US$500 million. Despite this intensive buyback campaign, selling pressure remains dominant and the stock continues to decline.</p><p>Within the Life Sciences Tools and Services sector, the entire WuXi group came under broad pressure. WuXi Biologics fell 4.81%, WuXi AppTec fell 4.7%, GenScript Biotech fell 4.3%, XtalPi fell 3.1%, and Insilico fell 2.01%, reflecting persistent sector-wide headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1134928472","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134928472","pubTimestamp":1780969749,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 9, WuXi XDC fell 3.59% in regular trading, trading at HK$44.94/share, with trading volume of HK$46.07 million. The stock has now dropped over 21% below its recent buyback average price of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"动向预警|药明新发常规交易下跌3.59%，回购努力未能遏制药明集团的抛售压力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On June 9, WuXi XDC fell 3.59% in regular trading, trading at HK$44.94/share, with trading volume of HK$46.07 million. The stock has now dropped over 21% below its recent buyback average price of HK$57.3, signaling deepening weakness.On the news front, the company previously disclosed that its professional trustee repurchased 5.702 million shares at an average price of HK$57.3, totaling approximately HK$327 million. Parent company WuXi Biologics also has a buyback plan of up to US$400 million, bringing the WuXi group total repurchase scale to US$500 million. Despite this intensive buyback campaign, selling pressure remains dominant and the stock continues to decline.Within the Life Sciences Tools and Services sector, the entire WuXi group came under broad pressure. WuXi Biologics fell 4.81%, WuXi AppTec fell 4.7%, GenScript Biotech fell 4.3%, XtalPi fell 3.1%, and Insilico fell 2.01%, reflecting persistent sector-wide headwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134928472","isCrawlerRequest":true}